Search

Your search keyword '"Xie, Zhuoer"' showing total 336 results
Start Over Author "Xie, Zhuoer"
336 results on '"Xie, Zhuoer"'

1. Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence.

Author

Xie, Zhuoer, Komrokji, Rami S, Al-Ali, Najla, Regelson, Alexandra, Geyer, Susan, Patel, Anand A, Saygin, Caner, Zeidan, Amer M, Bewersdorf, Jan Philipp, Mendez, Lourdes M, Kishtagari, Ashwin, Zeidner, Joshua F, Coombs, Catherine C, Madanat, Yazan F, Chung, Stephen S, Badar, Talha, Foran, James M, Desai, Pinkal, Tsai, Charlton, Griffiths, Elizabeth A, Al Malki, Monzr M, Amanam, Idoroenyi, Lai, Catherine, Deeg, H Joachim, Ades, Lionel, Arana-Yi, Cecilia, Osman, Afaf Eg, Dinner, Shira Naomi, Abaza, Yasmin, Taylor, Justin, Chandhok, Namrata S, Soong, Deborah, Brunner, Andrew M, Carraway, Hetty E, Singh, Abhay, Elena, Chiara, Ferrari, Jacqueline, Galli, Anna, Pozzi, Sara, Padron, Eric, Patnaik, Mrinal M, Malcovati, Luca, Savona, Michael R, and Al-Kali, Aref

Subjects
Cardiorespiratory Medicine and Haematology, Clinical Sciences, Paediatrics and Reproductive Medicine, Immunology, Biochemistry and cell biology, Cardiovascular medicine and haematology, Paediatrics
Abstract

Clonal cytopenia of undetermined significance (CCUS) represents a distinct disease entity characterized by myeloid-related somatic mutations with a variant allele fraction of ≥2% in individuals with unexplained cytopenia(s) but without a myeloid neoplasm (MN). Notably, CCUS carries a risk of progressing to MN, particularly in cases featuring high-risk mutations. Understanding CCUS requires dedicated studies to elucidate its risk factors and natural history. Our analysis of 357 CCUS patients investigated the interplay between clonality, cytopenia, and prognosis. Multivariate analysis identified 3 key adverse prognostic factors: the presence of splicing mutation(s) (score = 2 points), platelet count

Published
2024

2. A Combination of Indoor Localization and Wearable Sensor–Based Physical Activity Recognition to Assess Older Patients Undergoing Subacute Rehabilitation: Baseline Study Results

Author

Ramezani, Ramin, Zhang, Wenhao, Xie, Zhuoer, Shen, John, Elashoff, David, Roberts, Pamela, Stanton, Annette, Eslami, Michelle, Wenger, Neil, Sarrafzadeh, Majid, and Naeim, Arash

Subjects
Information technology, T58.5-58.64, Public aspects of medicine, RA1-1270
Abstract

BackgroundHealth care, in recent years, has made great leaps in integrating wireless technology into traditional models of care. The availability of ubiquitous devices such as wearable sensors has enabled researchers to collect voluminous datasets and harness them in a wide range of health care topics. One of the goals of using on-body wearable sensors has been to study and analyze human activity and functional patterns, thereby predicting harmful outcomes such as falls. It can also be used to track precise individual movements to form personalized behavioral patterns, to standardize the concept of frailty, well-being/independence, etc. Most wearable devices such as activity trackers and smartwatches are equipped with low-cost embedded sensors that can provide users with health statistics. In addition to wearable devices, Bluetooth low-energy sensors known as BLE beacons have gained traction among researchers in ambient intelligence domain. The low cost and durability of newer versions have made BLE beacons feasible gadgets to yield indoor localization data, an adjunct feature in human activity recognition. In the studies by Moatamed et al and the patent application by Ramezani et al, we introduced a generic framework (Sensing At-Risk Population) that draws on the classification of human movements using a 3-axial accelerometer and extracting indoor localization using BLE beacons, in concert. ObjectiveThe study aimed to examine the ability of combination of physical activity and indoor location features, extracted at baseline, on a cohort of 154 rehabilitation-dwelling patients to discriminate between subacute care patients who are re-admitted to the hospital versus the patients who are able to stay in a community setting. MethodsWe analyzed physical activity sensor features to assess activity time and intensity. We also analyzed activities with regard to indoor localization. Chi-square and Kruskal-Wallis tests were used to compare demographic variables and sensor feature variables in outcome groups. Random forests were used to build predictive models based on the most significant features. ResultsStanding time percentage (P

Published
2019
Full Text
View/download PDF

3. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease.

Author

Moey, Melissa, Hennessy, Cassandra, French, Benjamin, Warner, Jeremy, Tucker, Matthew, Hausrath, Daniel, Shah, Dimpy, DeCara, Jeanne, Bakouny, Ziad, Labaki, Chris, Choueiri, Toni, Dent, Susan, Akhter, Nausheen, Ismail-Khan, Roohi, Tachiki, Lisa, Slosky, David, Polonsky, Tamar, Awosika, Joy, Crago, Audrey, Wise-Draper, Trisha, Balanchivadze, Nino, Hwang, Clara, Fecher, Leslie, Gomez, Cyndi, Hayes-Lattin, Brandon, Glover, Michael, Shah, Sumit, Gopalakrishnan, Dharmesh, Griffiths, Elizabeth, Kwon, Daniel, Koshkin, Vadim, Mahmood, Sana, Bashir, Babar, Nonato, Taylor, Razavi, Pedram, McKay, Rana, Nagaraj, Gayathri, Oligino, Eric, Puc, Matthew, Tregubenko, Polina, Wulff-Burchfield, Elizabeth, Xie, Zhuoer, Halfdanarson, Thorvardur, Farmakiotis, Dimitrios, Klein, Elizabeth, Robilotti, Elizabeth, Riely, Gregory, Durand, Jean-Bernard, Hayek, Salim, Kondapalli, Lavanya, Berg, Stephanie, OConnor, Timothy, Bilen, Mehmet, Castellano, Cecilia, Accordino, Melissa, Sibel, Blau, Weissmann, Lisa, Jani, Chinmay, Flora, Daniel, Rudski, Lawrence, Dutra, Miriam, Nathaniel, Bouganim, Ruíz-García, Erika, Vilar-Compte, Diana, Gupta, Shilpa, Morgans, Alicia, and Nohria, Anju

Subjects
COVID-19 outcomes, Cancer, Cardio-oncology, Cardiovascular disease
Abstract

BACKGROUND: Data regarding outcomes among patients with cancer and co-morbid cardiovascular disease (CVD)/cardiovascular risk factors (CVRF) after SARS-CoV-2 infection are limited. OBJECTIVES: To compare Coronavirus disease 2019 (COVID-19) related complications among cancer patients with and without co-morbid CVD/CVRF. METHODS: Retrospective cohort study of patients with cancer and laboratory-confirmed SARS-CoV-2, reported to the COVID-19 and Cancer Consortium (CCC19) registry from 03/17/2020 to 12/31/2021. CVD/CVRF was defined as established CVD or no established CVD, male ≥ 55 or female ≥ 60 years, and one additional CVRF. The primary endpoint was an ordinal COVID-19 severity outcome including need for hospitalization, supplemental oxygen, intensive care unit (ICU), mechanical ventilation, ICU or mechanical ventilation plus vasopressors, and death. Secondary endpoints included incident adverse CV events. Ordinal logistic regression models estimated associations of CVD/CVRF with COVID-19 severity. Effect modification by recent cancer therapy was evaluated. RESULTS: Among 10,876 SARS-CoV-2 infected patients with cancer (median age 65 [IQR 54-74] years, 53% female, 52% White), 6253 patients (57%) had co-morbid CVD/CVRF. Co-morbid CVD/CVRF was associated with higher COVID-19 severity (adjusted OR: 1.25 [95% CI 1.11-1.40]). Adverse CV events were significantly higher in patients with CVD/CVRF (all p

Published
2023

5. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

Author

Aakash, Fnu, Gisriel, Savanah D., Zeidan, Amer M., Bennett, John M., Bejar, Rafael, Bewersdorf, Jan Philipp, Borate, Uma M., Boultwood, Jacqueline, Brunner, Andrew M., Buckstein, Rena, Carraway, Hetty E., Churpek, Jane E., Daver, Naval G., DeZern, Amy E., Efficace, Fabio, Fenaux, Pierre, Figueroa, Maria E., Garcia-Manero, Guillermo, Gore, Steven D., Greenberg, Peter L., Griffiths, Elizabeth A., Halene, Stephanie, Hourigan, Christopher S., Kim, Tae Kon, Kim, Nina, Komrokji, Rami S., Kutchroo, Vijay K., List, Alan F., Little, Richard F., Majeti, Ravindra, Nazha, Aziz, Nimer, Stephen D., Odenike, Olatoyosi, Padron, Eric, Patnaik, Mrinal M., Platzbecker, Uwe, Della Porta, Matteo G., Roboz, Gail J., Sallman, David A., Santini, Valeria, Sanz, Guillermo, Savona, Michael R., Sekeres, Mikkael A., Stahl, Maximilian, Starczynowski, Daniel T., Steensma, David P., Taylor, Justin, Abdel-Wahab, Omar, Wei, Andrew H., Xie, Zhuoer, Xu, Mina L., Hasserjian, Robert P., and Loghavi, Sanam

Published
2024
Full Text
View/download PDF

8. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

Author

Stahl, Maximilian, Bewersdorf, Jan Philipp, Xie, Zhuoer, Porta, Matteo Giovanni Della, Komrokji, Rami, Xu, Mina L., Abdel-Wahab, Omar, Taylor, Justin, Steensma, David P., Starczynowski, Daniel T., Sekeres, Mikkael A., Sanz, Guillermo, Sallman, David A., Roboz, Gail J., Platzbecker, Uwe, Patnaik, Mrinal M., Padron, Eric, Odenike, Olatoyosi, Nimer, Stephen D., Nazha, Aziz, Majeti, Ravi, Loghavi, Sanam, Little, Richard F., List, Alan F., Kim, Tae Kon, Hourigan, Christopher S., Hasserjian, Robert P., Halene, Stephanie, Griffiths, Elizabeth A., Gore, Steven D., Greenberg, Peter, Figueroa, Maria E., Fenaux, Pierre, Efficace, Fabio, DeZern, Amy E., Daver, Naval G., Churpek, Jane E., Carraway, Hetty E., Buckstein, Rena, Brunner, Andrew M., Boultwood, Jacqueline, Borate, Uma, Bejar, Rafael, Bennett, John M., Wei, Andrew H., Santini, Valeria, Savona, Michael R., and Zeidan, Amer M.

Published
2023
Full Text
View/download PDF

10. Electronic Video Consent to Power Precision Research: A Pilot Cohort Study

Author

Naeim, Arash, Dry, Sarah, Elashoff, David, Xie, Zhuoer, Petruse, Antonia, Magyar, Clara, Johansen, Lilliana, Werre, Gabriela, Lajonchere, Clara, and Wenger, Neil

Subjects
Health Services and Systems, Health Sciences, Precision Medicine, Genetics, Clinical Research, Human Genome, Good Health and Well Being, biobanking, precision medicine, electronic consent, privacy, pilot study, video, consent, precision innovation, efficient, precision, medicine, cancer, education, barrier, engagement, participation, innovation, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundDeveloping innovative, efficient, and institutionally scalable biospecimen consent for remnant tissue that meets the National Institutes of Health consent guidelines for genomic and molecular analysis is essential for precision medicine efforts in cancer.ObjectiveThis study aims to pilot-test an electronic video consent that individuals could complete largely on their own.MethodsThe University of California, Los Angeles developed a video consenting approach designed to be comprehensive yet fast (around 5 minutes) for providing universal consent for remnant biospecimen collection for research. The approach was piloted in 175 patients who were coming in for routine services in laboratory medicine, radiology, oncology, and hospital admissions. The pilot yielded 164 completed postconsent surveys. The pilot assessed the usefulness, ease, and trustworthiness of the video consent. In addition, we explored drivers for opting in or opting out.ResultsThe pilot demonstrated that the electronic video consent was well received by patients, with high scores for usefulness, ease, and trustworthiness even among patients that opted out of participation. The revised more animated video pilot test in phase 2 was better received in terms of ease of use (P=.005) and the ability to understand the information (P

Published
2021

11. Correction: Electronic Video Consent to Power Precision Health Research: A Pilot Cohort Study

Author

Naeim, Arash, Dry, Sarah, Elashoff, David, Xie, Zhuoer, Petruse, Antonia, Magyar, Clara, Johansen, Liliana, Werre, Gabriela, Lajonchere, Clara, and Wenger, Neil

Subjects
Health Services and Systems, Health Sciences, Good Health and Well Being, Biomedical and clinical sciences, Health sciences
Abstract

[This corrects the article DOI: 10.2196/29123.].

Published
2021

13. Spectrum of clonal hematopoiesis in VEXAS syndrome

Author

Gutierrez-Rodrigues, Fernanda, Kusne, Yael, Fernandez, Jenna, Lasho, Terra, Shalhoub, Ruba, Ma, Xiaoyang, Alessi, Hugh, Finke, Christy, Koster, Matthew J., Mangaonkar, Abhishek, Warrington, Kenneth J., Begna, Kebede, Xie, Zhuoer, Ombrello, Amanda K., Viswanatha, David, Ferrada, Marcela, Wilson, Lorena, Go, Ronald, Kourelis, Taxiarchis, Reichard, Kaaren, Olteanu, Horatiu, Darden, Ivana, Hironaka, Dalton, Alemu, Lemlem, Kajigaya, Sachiko, Rosenzweig, Sofia, Calado, Rodrigo T., Groarke, Emma M., Kastner, Daniel L., Calvo, Katherine R., Wu, Colin O., Grayson, Peter C., Young, Neal S., Beck, David B., Patel, Bhavisha A., and Patnaik, Mrinal M.

Published
2023
Full Text
View/download PDF

14. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)

Author

Bewersdorf, Jan Philipp, Xie, Zhuoer, Bejar, Rafael, Borate, Uma, Boultwood, Jacqueline, Brunner, Andrew M., Buckstein, Rena, Carraway, Hetty E., Churpek, Jane E., Daver, Naval G., Porta, Matteo Giovanni Della, DeZern, Amy E., Fenaux, Pierre, Figueroa, Maria E., Gore, Steven D., Griffiths, Elizabeth A., Halene, Stephanie, Hasserjian, Robert P., Hourigan, Christopher S., Kim, Tae Kon, Komrokji, Rami, Kuchroo, Vijay K., List, Alan F., Loghavi, Sanam, Majeti, Ravindra, Odenike, Olatoyosi, Patnaik, Mrinal M., Platzbecker, Uwe, Roboz, Gail J., Sallman, David A., Santini, Valeria, Sanz, Guillermo, Sekeres, Mikkael A., Stahl, Maximilian, Starczynowski, Daniel T., Steensma, David P., Taylor, Justin, Abdel-Wahab, Omar, Xu, Mina L., Savona, Michael R., Wei, Andrew H., and Zeidan, Amer M.

Published
2023
Full Text
View/download PDF

15. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Author

Kuderer, Nicole M, Choueiri, Toni K, Shah, Dimpy P, Shyr, Yu, Rubinstein, Samuel M, Rivera, Donna R, Shete, Sanjay, Hsu, Chih-Yuan, Desai, Aakash, de Lima Lopes, Gilberto, Grivas, Petros, Painter, Corrie A, Peters, Solange, Thompson, Michael A, Bakouny, Ziad, Batist, Gerald, Bekaii-Saab, Tanios, Bilen, Mehmet A, Bouganim, Nathaniel, Larroya, Mateo Bover, Castellano, Daniel, Del Prete, Salvatore A, Doroshow, Deborah B, Egan, Pamela C, Elkrief, Arielle, Farmakiotis, Dimitrios, Flora, Daniel, Galsky, Matthew D, Glover, Michael J, Griffiths, Elizabeth A, Gulati, Anthony P, Gupta, Shilpa, Hafez, Navid, Halfdanarson, Thorvardur R, Hawley, Jessica E, Hsu, Emily, Kasi, Anup, Khaki, Ali R, Lemmon, Christopher A, Lewis, Colleen, Logan, Barbara, Masters, Tyler, McKay, Rana R, Mesa, Ruben A, Morgans, Alicia K, Mulcahy, Mary F, Panagiotou, Orestis A, Peddi, Prakash, Pennell, Nathan A, Reynolds, Kerry, Rosen, Lane R, Rosovsky, Rachel, Salazar, Mary, Schmidt, Andrew, Shah, Sumit A, Shaya, Justin A, Steinharter, John, Stockerl-Goldstein, Keith E, Subbiah, Suki, Vinh, Donald C, Wehbe, Firas H, Weissmann, Lisa B, Wu, Julie Tsu-Yu, Wulff-Burchfield, Elizabeth, Xie, Zhuoer, Yeh, Albert, Yu, Peter P, Zhou, Alice Y, Zubiri, Leyre, Mishra, Sanjay, Lyman, Gary H, Rini, Brian I, Warner, Jeremy L, Consortium, COVID-19 and Cancer, Abidi, Maheen, Acoba, Jared D, Agarwal, Neeraj, Ahmad, Syed, Ajmera, Archana, Altman, Jessica, Angevine, Anne H, Azad, Nilo, Bar, Michael H, Bardia, Aditya, Barnholtz-Sloan, Jill, Barrow, Briana, Bashir, Babar, Belenkaya, Rimma, Berg, Stephanie, Bernicker, Eric H, Bestvina, Christine, Bishnoi, Rohit, Boland, Genevieve, Bonnen, Mark, Bouchard, Gabrielle, Bowles, Daniel W, Busser, Fiona, Cabal, Angelo, Caimi, Paolo, and Carducci, Theresa

Subjects
Biomedical and Clinical Sciences, Health Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Aging, Prevention, Cancer, Lung, Good Health and Well Being, Aged, Antiviral Agents, Azithromycin, Betacoronavirus, COVID-19, Cause of Death, Comorbidity, Coronavirus Infections, Databases, Factual, Female, Humans, Hydroxychloroquine, Male, Middle Aged, Neoplasms, Pandemics, Pneumonia, Viral, Prognosis, Risk Factors, SARS-CoV-2, COVID-19 Drug Treatment, COVID-19 and Cancer Consortium, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundData on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness.MethodsIn this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing.FindingsOf 1035 records entered into the CCC19 database during the study period, 928 patients met inclusion criteria for our analysis. Median age was 66 years (IQR 57-76), 279 (30%) were aged 75 years or older, and 468 (50%) patients were male. The most prevalent malignancies were breast (191 [21%]) and prostate (152 [16%]). 366 (39%) patients were on active anticancer treatment, and 396 (43%) had active (measurable) cancer. At analysis (May 7, 2020), 121 (13%) patients had died. In logistic regression analysis, independent factors associated with increased 30-day mortality, after partial adjustment, were: increased age (per 10 years; partially adjusted odds ratio 1·84, 95% CI 1·53-2·21), male sex (1·63, 1·07-2·48), smoking status (former smoker vs never smoked: 1·60, 1·03-2·47), number of comorbidities (two vs none: 4·50, 1·33-15·28), Eastern Cooperative Oncology Group performance status of 2 or higher (status of 2 vs 0 or 1: 3·89, 2·11-7·18), active cancer (progressing vs remission: 5·20, 2·77-9·77), and receipt of azithromycin plus hydroxychloroquine (vs treatment with neither: 2·93, 1·79-4·79; confounding by indication cannot be excluded). Compared with residence in the US-Northeast, residence in Canada (0·24, 0·07-0·84) or the US-Midwest (0·50, 0·28-0·90) were associated with decreased 30-day all-cause mortality. Race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.InterpretationAmong patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments.FundingAmerican Cancer Society, National Institutes of Health, and Hope Foundation for Cancer Research.

Published
2020

16. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes

Author

Zeidan, Amer M., Bewersdorf, Jan Philipp, Buckstein, Rena, Sekeres, Mikkael A., Steensma, David P., Platzbecker, Uwe, Loghavi, Sanam, Boultwood, Jacqueline, Bejar, Rafael, Bennett, John M., Borate, Uma, Brunner, Andrew M., Carraway, Hetty, Churpek, Jane E., Daver, Naval G., Della Porta, Matteo, DeZern, Amy E., Efficace, Fabio, Fenaux, Pierre, Figueroa, Maria E., Greenberg, Peter, Griffiths, Elizabeth A., Halene, Stephanie, Hasserjian, Robert P., Hourigan, Christopher S., Kim, Nina, Kim, Tae Kon, Komrokji, Rami S., Kutchroo, Vijay, List, Alan F., Little, Richard F., Majeti, Ravi, Nazha, Aziz, Nimer, Stephen D., Odenike, Olatoyosi, Padron, Eric, Patnaik, Mrinal M., Roboz, Gail J., Sallman, David A., Sanz, Guillermo, Stahl, Maximilian, Starczynowski, Daniel T., Taylor, Justin, Xie, Zhuoer, Xu, Mina, Savona, Michael R., Wei, Andrew H., Abdel-Wahab, Omar, and Santini, Valeria

Published
2022
Full Text
View/download PDF

17. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms

Author

Patnaik, Mrinal M., Zeidan, Amer M., Padron, Eric, Platzbecker, Uwe, Sallman, David A., DeZern, Amy E., Bejar, Rafael, Sekeres, Mikkael, Taylor, Justin, Little, Richard F., Bewersdorf, Jan P., Kim, Tae Kon., Kim, Nina, Hourigan, Christopher S., Dela Porta, Matteo G., Stahl, Maximilian, Steensma, David, Xu, Mina L., Odenike, Olatoyosi, Carraway, Hetty, Fenaux, Pierre, Nazha, Aziz, Komrokji, Rami, Loghavi, Sanam, Xie, Zhuoer, Hasserjian, Robert, Savona, Michael, and Bennett, John M.

Published
2022
Full Text
View/download PDF

18. Contributors

Author

AK, Ghosh, primary, Ali, Mohamed S., additional, Alvarez-Cardona, Jose A., additional, Balanescu, Dinu Valentin, additional, Barata, Pedro C., additional, Bouberhan, Sara, additional, Büdeyri, Ibrahim, additional, Cannistra, Stephen A., additional, Carver, Joseph R., additional, Chuy, Katherine Lee, additional, Clasen, Suparna C., additional, Connolly, H.M., additional, Costello, Brian A., additional, DH, Chen, additional, Dispenzieri, Angela, additional, Dobbin, Stephen J.H., additional, Donisan, Teodora, additional, Eschenhagen, Thomas, additional, Finch, William, additional, Fradley, Michael, additional, Francis, Sanjeev A., additional, Gallardo-Grajeda, Andrea, additional, Galsky, Matthew D., additional, Geyer, Alexander, additional, Grothey, Axel, additional, Habermann, Thomas M., additional, Haddad, Robert I., additional, Halfdanarson, Thorvardur R., additional, Hallemeier, Christopher L., additional, Herrmann, Joerg, additional, Herrmann, Sandra M.S., additional, Hogan, William, additional, Iliescu, Cezar, additional, Jones, Robin, additional, Kaley, Thomas J., additional, Kaur, Jasvinder, additional, Khorana, Alok A., additional, Klarich, Kyle W., additional, Kleeff, Jörg, additional, Kondapalli, Lavanya, additional, Ky, Bonnie, additional, Lang, Ninian N., additional, Larsen, Carolyn M., additional, Lefebvre, Bénédicte, additional, Lenihan, Daniel J., additional, Liu, Jennifer E., additional, Luis, S.A., additional, Maamari, Dimitri J., additional, Makkar, Priyanka, additional, Maleszewskic, Joseph J., additional, McBane, Robert D., additional, McCullough, Kristen B., additional, Michalski, Christoph W., additional, Mogilevskaya, Yevgeniya, additional, Neilan, Tomas G., additional, Nkomo, Vuyisile T., additional, Oh, Jae K., additional, Patnaik, Mrinal M., additional, Pellikka, P.A., additional, Poudel, Shyam K., additional, Rassaf, Tienush, additional, Reardon, Michael J., additional, Ruddy, Kathryn J., additional, Sahni, Gagan, additional, Singh Sara, Jaskanwal Deep, additional, Sartor, Oliver, additional, Sawyer, Douglas, additional, Schadendorf, Dirk, additional, Schaffer, Wendy, additional, Scott, Jessica M., additional, Shea, Meghan, additional, Sonbol, Mohamed Bassam, additional, Spahillari, Aferdita, additional, Squires, Ray W., additional, Starr, Jason S., additional, Steingart, Richard, additional, Stewart, A. Keith, additional, Szucs, Zoltan, additional, Touyz, Rhian M., additional, Trachtenberg, Barry H., additional, Tuzovic, Mirela, additional, Varghese, Jeena, additional, Viscuse, Paul V., additional, Weeks, Lachelle D., additional, Xie, Zhuoer, additional, Yang, Eric H., additional, and Yu, Anthony, additional

Published
2023
Full Text
View/download PDF

19. Risk estimation, anxiety, and breast cancer worry in women at risk for breast cancer: A single‐arm trial of personalized risk communication

Author

Xie, Zhuoer, Wenger, Neil, Stanton, Annette L, Sepucha, Karen, Kaplan, Celia, Madlensky, Lisa, Elashoff, David, Trent, Jacqueline, Petruse, Antonia, Johansen, Liliana, Layton, Tracy, and Naeim, Arash

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Mental Health, Clinical Research, Genetic Testing, Genetics, Behavioral and Social Science, Cancer, Breast Cancer, Prevention, Good Health and Well Being, Adult, Anxiety, Breast Neoplasms, Communication, Early Detection of Cancer, Female, Genetic Counseling, Genetic Predisposition to Disease, Health Behavior, Humans, Mammography, Middle Aged, Risk Assessment, Risk Factors, Surveys and Questionnaires, anxiety, breast cancer worry, oncology, perceived risk, risk communication, Clinical Sciences, Psychology, Oncology & Carcinogenesis, Biomedical and clinical sciences
Abstract

ObjectiveElevated anxiety and breast cancer worry can impede mammographic screening and early breast cancer detection. Genetic advances and risk models make personalized breast cancer risk assessment and communication feasible, but it is unknown whether such communication of risk affects anxiety and disease-specific worry. We studied the effect of a personalized breast cancer screening intervention on risk perception, anxiety, and breast cancer worry.MethodsWomen with a normal mammogram but elevated risk for breast cancer (N = 122) enrolled in the Athena Breast Health risk communication program were surveyed before and after receiving a letter conveying their breast cancer risk and a breast health genetic counselor consultation. We compared breast cancer risk estimation, anxiety, and breast cancer worry before and after risk communication and evaluated the relationship of anxiety and breast cancer worry to risk estimation accuracy.ResultsWomen substantially overestimated their lifetime breast cancer risk, and risk communication somewhat mitigated this overestimation (49% pre-intervention, 42% post-intervention, 13% Gail model risk estimate, P < .001). Both general anxiety and breast cancer worry declined significantly after risk communication in women with high baseline anxiety. Baseline anxiety and breast cancer worry were essentially unrelated to risk estimation accuracy, but risk communication increased alignment of worry with accuracy of risk assessment.ConclusionsPersonalized communication about breast cancer risk was associated with modestly improved risk estimation accuracy in women with relatively low anxiety and less anxiety and breast cancer worry in women with higher anxiety. We detected no negative consequences of informing women about elevated breast cancer risk.

Published
2019

21. Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia.

Author

Mims, Alice, Xie, Zhuoer, Potluri, Ravi, Rotter, David, Chevli, Manoj, Prebet, Thomas, Gaugler, Lona, Strocchia, Maria, Vasconcelos, Alberto, and Sieluk, Jan

Subjects
*ACUTE myeloid leukemia, *VENETOCLAX, *OVERALL survival, *AZACITIDINE, *DATABASES
Abstract

AbstractOral azacitidine (Oral-AZA) is recommended as maintenance therapy for patients with newly diagnosed acute myeloid leukemia (ND AML) achieving remission with intensive chemotherapy (IC) but not transplant candidates; venetoclax plus injectable azacitidine (VEN-AZA) is recommended for patients ineligible for IC. Some patients may be considered candidates for either regimen. This retrospective study used Flatiron Health’s database to compare treatment patterns and clinical outcomes with Oral-AZA maintenance after IC (ICOral-AZA) versus frontline VEN-AZA. Relapse-free survival (RFS) and overall survival (OS) were analyzed at 4 different time points, including from Oral-AZA initiation (ICOral-AZA cohort) or from remission (VEN-AZA cohort) in the Core Analysis. Median RFS was 14.9 and 8.1 months for ICOral-AZA and VEN-AZA propensity score-matched cohorts, in the Core Analysis (n = 32 in each; p = 0.027); median OS was 18.7 and 15.2 months (p = 0.034). In patients with AML, ICOral-AZA significantly improved RFS and OS compared with VEN-AZA. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

Author

Efficace, Fabio, primary, Buckstein, Rena, additional, Abel, Gregory A., additional, Giesinger, Johannes M., additional, Fenaux, Pierre, additional, Bewersdorf, Jan Philipp, additional, Brunner, Andrew M., additional, Bejar, Rafael, additional, Borate, Uma, additional, DeZern, Amy E., additional, Greenberg, Peter, additional, Roboz, Gail J., additional, Savona, Michael R., additional, Sparano, Francesco, additional, Boultwood, Jacqueline, additional, Komrokji, Rami, additional, Sallman, David A., additional, Xie, Zhuoer, additional, Sanz, Guillermo, additional, Carraway, Hetty E., additional, Taylor, Justin, additional, Nimer, Stephen D., additional, Della Porta, Matteo Giovanni, additional, Santini, Valeria, additional, Stahl, Maximilian, additional, Platzbecker, Uwe, additional, Sekeres, Mikkael A., additional, and Zeidan, Amer M., additional

Published
2024
Full Text
View/download PDF

30. Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities

Author

Horvat, Nathan P., primary, Abdallah, Enas F., additional, Xie, Zhuoer, additional, Al Ali, Najla, additional, Yun, Seongseok, additional, Walker, Alison, additional, Padron, Eric, additional, Sallman, David, additional, Chan, Onyee, additional, Lancet, Jeffrey, additional, Komrokji, Rami, additional, and Kuykendall, Andrew T., additional

Published
2023
Full Text
View/download PDF

31. Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience

Author

Nanaa, Ahmad, Viswanatha, David, Xie, Zhuoer, Jevremovic, Dragan, Nguyen, Phuong, Salama, Mohamad E., Greipp, Patricia, Bessonen, Kurt, Gangat, Naseema, Patnaik, Mrinal, Pardanani, Animesh, Alkhateeb, Hassan B., Shah, Mithun, Hogan, William, Tefferi, Ayalew, Litzow, Mark, He, Rong, and Al-Kali, Aref

Published
2021
Full Text
View/download PDF

35. POSTER: AML-068 Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but Not Treated in a US Electronic Health Record (EHR) Database

Author

Mims, Alice, primary, Xie, Zhuoer, additional, Vasconcelos, Alberto, additional, Strocchia, Maria, additional, Heydendael, Willem, additional, Chevli, Manoj, additional, Rotter, David, additional, Potluri, Ravi, additional, Prebet, Thomas, additional, and Sieluk, Jan, additional

Published
2023
Full Text
View/download PDF

36. Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy

Author

Xie, Zhuoer, primary, Lasho, Terra, additional, Khurana, Arushi, additional, Ferrer, Alejandro, additional, Finke, Christy, additional, Mangaonkar, Abhishek A., additional, Ansell, Stephen, additional, Fernandez, Jenna, additional, Shah, Mithun Vinod, additional, Al-Kali, Aref, additional, Gangat, Naseema, additional, Abeykoon, Jithma, additional, Witzig, Thomas E., additional, and Patnaik, Mrinal M., additional

Published
2023
Full Text
View/download PDF

37. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease

Author

Moey, Melissa Y.Y., primary, Hennessy, Cassandra, additional, French, Benjamin, additional, Warner, Jeremy L., additional, Tucker, Matthew D., additional, Hausrath, Daniel J., additional, Shah, Dimpy P., additional, DeCara, Jeanne M., additional, Bakouny, Ziad, additional, Labaki, Chris, additional, Choueiri, Toni K., additional, Dent, Susan, additional, Akhter, Nausheen, additional, Ismail-Khan, Roohi, additional, Tachiki, Lisa, additional, Slosky, David, additional, Polonsky, Tamar S., additional, Awosika, Joy A., additional, Crago, Audrey, additional, Wise-Draper, Trisha, additional, Balanchivadze, Nino, additional, Hwang, Clara, additional, Fecher, Leslie A., additional, Gomez, Cyndi Gonzalez, additional, Hayes-Lattin, Brandon, additional, Glover, Michael J., additional, Shah, Sumit A., additional, Gopalakrishnan, Dharmesh, additional, Griffiths, Elizabeth A., additional, Kwon, Daniel H., additional, Koshkin, Vadim S., additional, Mahmood, Sana, additional, Bashir, Babar, additional, Nonato, Taylor, additional, Razavi, Pedram, additional, McKay, Rana R., additional, Nagaraj, Gayathri, additional, Oligino, Eric, additional, Puc, Matthew, additional, Tregubenko, Polina, additional, Wulff-Burchfield, Elizabeth M., additional, Xie, Zhuoer, additional, Halfdanarson, Thorvardur R., additional, Farmakiotis, Dimitrios, additional, Klein, Elizabeth J., additional, Robilotti, Elizabeth V., additional, Riely, Gregory J., additional, Durand, Jean-Bernard, additional, Hayek, Salim S., additional, Kondapalli, Lavanya, additional, Berg, Stephanie, additional, O'Connor, Timothy E., additional, Bilen, Mehmet A., additional, Castellano, Cecilia, additional, Accordino, Melissa K., additional, Sibel, Blau, additional, Weissmann, Lisa B., additional, Jani, Chinmay, additional, Flora, Daniel B., additional, Rudski, Lawrence, additional, Dutra, Miriam Santos, additional, Nathaniel, Bouganim, additional, Ruíz-García, Erika, additional, Vilar-Compte, Diana, additional, Gupta, Shilpa, additional, Morgans, Alicia, additional, and Nohria, Anju, additional

Published
2023
Full Text
View/download PDF

38. S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)

Author

Komrokji, Rami S., primary, Ball, Somdeb, additional, Maggioni, Giulia, additional, Travaglino, Erica, additional, Al Ali, Najla, additional, Fenaux, Pierre, additional, Platzbecker, Uwe, additional, Santini, Valeria, additional, Díez Campelo, María, additional, Haferlach, Torsten, additional, Singh, Avani, additional, Jain, Akriti, additional, Aguirre, Luis E., additional, Tinsley, Sara, additional, Schwabkey, Zaker, additional, Chan, Onyee, additional, Xie, Zhuoer, additional, Brunner, Andrew, additional, Kuykendall, Andrew, additional, Bennett, John, additional, Buckstein, Rena, additional, Bejar, Rafael, additional, Bewersdorf, Jan, additional, Carraway, Hetty, additional, Dezern, Amy, additional, Griffiths, Elizabeth A., additional, Halene, Stephanie, additional, Hasserjian, Robert Paul, additional, Loghavi, Sanam, additional, Odenike, Olatoyosi, additional, Patnaik, Mrinal, additional, Roboz, Gail, additional, Stahl, Maximillian, additional, Sekeres, Mikkael, additional, Steensma, David, additional, Savona, Michael Robert, additional, Taylor, Justin, additional, Xu, Mina, additional, Sweet, Kendra, additional, Lancet, Jeffrey, additional, List, Alan, additional, Padron, Eric, additional, Sallman, David, additional, Zeidan, Amer M., additional, and Della Porta, Matteo Giovanni, additional

Published
2023
Full Text
View/download PDF

39. Updates in classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium of MDS (icMDS)

Author

Stahl, Maximilian, primary, Bewersdorf, Jan Philipp, additional, Xie, Zhuoer, additional, Porta, Matteo Giovanni Della, additional, Komrokji, Rami, additional, Xu, Mina L., additional, Abdel-Wahab, Omar, additional, Taylor, Justin, additional, Steensma, David P., additional, Starczynowski, Daniel T., additional, Sekeres, Mikkael A., additional, Sanz, Guillermo, additional, Sallman, David A., additional, Roboz, Gail J., additional, Platzbecker, Uwe, additional, Patnaik, Mrinal M., additional, Padron, Eric, additional, Odenike, Olatoyosi, additional, Nimer, Stephen D., additional, Nazha, Aziz, additional, Majeti, Ravi, additional, Loghavi, Sanam, additional, Little, Richard F., additional, List, Alan F., additional, Kim, Tae Kon, additional, Hourigan, Christopher S., additional, Hasserjian, Robert P., additional, Halene, Stephanie, additional, Griffiths, Elizabeth A., additional, Gore, Steven D., additional, Greenberg, Peter, additional, Figueroa, Maria E., additional, Fenaux, Pierre, additional, Efficace, Fabio, additional, DeZern, Amy E., additional, Daver, Naval G., additional, Churpek, Jane E., additional, Carraway, Hetty E., additional, Buckstein, Rena, additional, Brunner, Andrew M., additional, Boultwood, Jacqueline, additional, Borate, Uma, additional, Bejar, Rafael, additional, Bennett, John M., additional, Wei, Andrew H., additional, Santini, Valeria, additional, Savona, Michael R., additional, and Zeidan, Amer M., additional

Published
2023
Full Text
View/download PDF

40. P727: REFINING RISK STRATIFICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A COMPREHENSIVE ASSESSMENT OF THE IPSS-M AND OTHER MOLECULARLY INTEGRATED PROGNOSTIC MODELS

Author

Aguirre, Luis E., primary, Jain, Akriti, additional, Ball, Somedeb, additional, Al Ali, Najla, additional, Sallman, David, additional, Kuykendall, Andrew, additional, Chan, Onyee, additional, Xie, Zhuoer, additional, Walker, Alison, additional, Sweet, Kendra, additional, Lancet, Jeffrey, additional, Padron, Eric, additional, and S. Komrokji, Rami, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results